GlassScriptPhysician profile
Nathaniel A Kho
NPI 1689757189
$6,911.02
in general payments reported to CMS, 2019-2025
38 companies · $56.21 in 2025
The $56.21 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,630 · 2020: $1,300 · 2021: $1,273 · 2022: $757 · 2023: $637 · 2024: $258 · 2025: $56.21.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $947 · Education: $3.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $947.29 |
| Education | $3.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $1,818.14 | 2019-2023 | Xadago, Apokyn |
| Abbvie INC. | $714.40 | 2019-2024 | |
| Ucb, INC. | $481.58 | 2019-2024 | Briviact, Fintepla |
| Sk Life Science, INC. | $473.48 | 2020-2024 | Xcopri |
| Alexion Pharmaceuticals, INC. | $441.95 | 2019-2020 | |
| Livanova USA, INC. | $245.69 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Amgen INC. | $234.94 | 2019-2022 | |
| Adamas Pharmaceuticals, INC. | $222.80 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $219.60 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $187.41 | 2019-2024 | Daybue |
| Greenwich Biosciences, INC. | $186.37 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $186.04 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $167.81 | 2021-2022 | |
| Neuronetics, INC. | $157.74 | 2021 | |
| Lilly USA, LLC | $104.60 | 2019-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $101.83 | 2019-2021 | |
| Life Molecular Imaging LTD | $98.85 | 2019-2021 | |
| Ge Healthcare | $96.17 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $85.01 | 2021 | |
| Eisai INC. | $80.67 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $73.04 | 2023 | Aptiom |
| Boston Scientific Corporation | $70.36 | 2021-2023 | Vercise |
| Argenx US, INC. | $61.09 | 2023-2024 | Vyvgart |
| Kyowa Kirin, INC. | $58.24 | 2019-2021 | |
| Allergan, INC. | $48.38 | 2020 | |
| Jazz Pharmaceuticals INC. | $48.32 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $40.81 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $32.03 | 2021 | |
| Biogen, INC. | $31.54 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $20.22 | 2023 | Nuedexta |
| Neurelis, INC. | $19.94 | 2023 | Valtoco |
| Alnylam Pharmaceuticals INC. | $19.52 | 2019 | |
| Natus Medical Incorporated | $15.50 | 2019 | |
| Pfizer INC. | $14.85 | 2025 | |
| Arbor Pharmaceuticals, INC. | $13.95 | 2019 | |
| Genzyme Corporation | $13.73 | 2022 | |
| Currax Pharmaceuticals LLC | $13.35 | 2021 | |
| Catalyst Pharmaceuticals, INC. | $11.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaniel Kho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.